Tempus的AI心脏成像工具得到FDA的批准, 使库存增加12%。 Tempus' AI cardiac imaging tool gets FDA approval, boosting stock by 12%.

医疗技术公司Tempus在其人工智能心脏成像平台Tempus Pixel获得FDA批准后,股价上了12%. Healthcare tech company Tempus saw its stock rise by 12% after its AI-powered cardiac imaging platform, Tempus Pixel, received FDA clearance. 经过更新的平台现在可以生成详细的心脏MR图像,帮助医生更准确地诊断心脏病。 The updated platform can now generate detailed cardiac MR images, helping doctors diagnose heart conditions more accurately. 通过这项许可,Tempus像素可以在美国诊所使用,有可能改善病人的护理,并为医疗诊断制定新的AI标准。 This clearance allows Tempus Pixel to be used in US clinics, potentially improving patient care and setting a new standard for AI in medical diagnostics.